Phase 3 Hospital-acquired Bacterial Pneumonia Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)Colistin Resistanrt ABC+1 more
BioVersys SAS248 enrolled1 locationNCT07326540
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Qilu Pharmaceutical Co., Ltd.420 enrolled1 locationNCT07327619
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)Complicated Intra-abdominal Infection (cIAI)+2 more
Qilu Pharmaceutical Co., Ltd.80 enrolled1 locationNCT07089186